Table 1.
Clinical features and SOX2 antibody and protein staining characteristics of SCLC patients
| n | Median survival (months) | P (log rank) | ||
|---|---|---|---|---|
| Age |
61 (44–78) |
|
|
|
| |
<60 |
24 |
10.36 |
0.76 |
| |
≥60 |
35 |
7.1 |
|
| LDH |
193 IU/L (133–380) |
|
|
|
| |
<200 |
30 |
10.75 |
0.36 |
| |
≥200 |
25 |
8.86 |
|
| |
U* |
4 |
|
|
| AP |
93 IU/L (50-171 |
|
|
|
| |
<70 |
14 |
3.97 |
0.47 |
| |
≥70 |
44 |
8.68 |
|
| |
U |
1 |
|
|
| Stage |
Limited |
28 |
10.36 |
0.03 |
| |
Extensive |
27 |
7.34 |
|
| |
U |
1 |
|
|
| SOX2 antibody |
<M + 2SD |
42 |
8.68 |
0.3 |
| |
≥ M + 2SD |
17 |
7.85 |
|
| SOX2 IHC intensity** |
0-1 |
25 |
7.39 |
0.98 |
| |
2-3 |
30 |
10.65 |
|
| SOX2 IHC frequency |
<5 % |
16 |
25.87 |
0.12 |
| |
≥5 % |
39 |
7.39 |
|
| SOX2 IHC frequency |
<20 % |
24 |
7.4 |
0.11 |
| |
≥20 % |
31 |
7.86 |
|
| SOX2 IHC frequency |
<40 % |
29 |
7.39 |
0.43 |
| ≥40 % | 26 | 9.68 |
*U: unknown. **Tumor tissue sections evaluations were available from 55 patients.